What question did this study set out to answer?

To assess the impact of high-efficacy disease-modifying therapies (HE-DMTs) on neurological function in individuals at varying risk of aggressive multiple sclerosis (MS).

April 7, 2026Open Access

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

Puntos clave

To assess the impact of high-efficacy disease-modifying therapies (HE-DMTs) on neurological function in individuals at varying risk of aggressive multiple sclerosis (MS).
Conducted an observational cohort study
Compared outcomes between HE-DMT-treated and untreated groups
Evaluated relapse rates and disability outcomes among patients using HE-DMT
HE-DMTs reduced relapse rates in both high and low risk MS patients
No significant difference in long-term disability outcomes between treated and untreated individuals
Disability worsening was less frequent in patients treated with HE-DMT

Resumen

HE-DMTs reduced the risk of relapse in people at both high and low risk of aggressive MS, with no evidence of differential treatment benefit. In the overall population, no evidence of a difference in disability outcomes between HE-DMT-treated and HE-DMT-untreated time was observed. However, among patients ever exposed to HE-DMT, disability worsening was less common while treated with HE-DMT.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Roos et al. (Sat,) studied this question.

synapsesocial.com/papers/69d49ecbb33cc4c35a227833 https://doi.org/https://doi.org/10.1007/s40263-026-01287-8

Me gusta

Guardar

Ver artículo completo